A class action lawsuit was filed against medical device company Boston Scientific (BSX) on March 5, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Plaintiffs -shareholders- in the federal securities class action allege that they acquired Boston Scientific Corporation stock at artificially inflated prices between July 23, 2025 and February 3, 2026, known as the Class Period. They are now seeking compensation for financial losses incurred upon public revelation of the company’s alleged misconduct during that time. To learn whether you may be eligible for a recovery under this securities lawsuit, click here.
What Does Boston Scientific Do?
Boston Scientific is a medical device company. As such, it engages in the development, manufacturing and marketing tools that are used in various “interventional medical specialties” globally. To that end, Boston Scientific has several “core businesses,” which include but are not limited to: Cardiac Rhythm Management, Urology, Endoscopy, and Electrophysiology (EP).
According to the company, EP is responsible for developing, making and marketing devices such as the FarapulsePFA system. These devices are mostly used to identify and treat heart rhythm disorders. But that is not all. The company also claims that these devices are designed to simplify cardiac ablation procedures. Cardiac ablation is a treatment for some kinds of irregular heart rhythms (arrhythmias).
The company’s claims about its U.S. EP Segment are at the crux of the current complaint.
Why are Shareholders Suing Boston Scientific?
Boston Scientific and five of its senior executives (the “Individual Defendants”) are now accused of deceiving investors by lying and withholding important information about the company’s business and prospects during the Class Period.
In particular, they are accused of omitting truthful information about the sustainability of Boston Scientific’s U.S. EP segment’s growth rate from SEC filings and related material. By knowingly or recklessly doing so, they allegedly caused Boston Scientific’s stock to trade at artificially inflated prices during the time in question. The truth, according to shareholders, came out in a press release published by the company on February 4, 2026. In it, Boston Scientific shared that it experienced a poor performance in terms of U.S. EP Segment sales for the fourth quarter and full year 2025, among other things. As detailed in the complaint, the company blamed its poor results on “a combination of slower than expected market growth alongside increased competition[.]”
Taking a Closer Look
As alleged, Boston Scientific and/or the Individual Defendants repeatedly made false and misleading public statements throughout the Class Period.
In a press release issued at the beginning of the Class Period, for example, Boston Scientific’s CEO (an Individual Defendant) stated in relevant part: “This was another excellent quarter — marked by exceptional top-line performance — that delivered margin expansion and prioritized investment for future growth. I am incredibly grateful to our dedicated global team for demonstrating clinical and commercial excellence across the company and positioning us for differentiated long-term performance.”
During an earnings call that same day, the company’s CEO also stated in relevant part: “Electrophysiology sales grew 94%, lapping our first full quarter of the FARAPULSE launch in the U.S. and growing mid-teens sequentially[…]”
Next, during the company’s Analyst/Investor Day Conference on September 30, 2025, the company’s Executive Vice President and Group President of Cardiology (an Individual Defendant) stated in pertinent part: “So we see over the long-range plan, the EP market growing at 15% and Nick and Dr. Sutton will talk about how we’re going to outpace the market. The basic headline there is we will continue to take share in the broad EP market, and we will enter portions of the EP market that we’re not in today[…]”
Finally, during an October 22, 2025 earnings call, Boston Scientific’s CEO stated in pertinent part: “Turning to EP. We’re incredibly proud of our EP performance, with third quarter sales growing 63% as we drive continued share gains in the overall EP market.”
Actions You May Take
If you have purchased the company’s stock during the Class Period, you may join the class action as a lead plaintiff, remain a passive class member, or opt out of this litigation and pursue individual claims that may not be available to the class as a whole. To learn more about your options, click here.
The deadline to file for lead plaintiff in this class action is May 4, 2026.